A pivotal platform study leveraging circulating tumor DNA (ctDNA) has demonstrated the capacity to guide adjuvant chemotherapy intensification in colon cancer patients by detecting minimal residual disease (MRD). Published in BMC Cancer, this research heralds a move towards more personalized postoperative treatment strategies, potentially improving patient outcomes and reducing unnecessary chemotherapy exposure.